Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG | P07510 | 1/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7704772 | 1.00 | PNMT (0.59) | PNMTOPRK1SLC6A2HRH1SLC6A3 | |
| Hydrochloric Acid SCHEMBL7714557 | 0.98 | PNMT (0.57) | PNMTOPRK1SLC6A2HRH1SLC6A3 | |
| SCHEMBL1226845 | 0.84 | CYP2B6 (0.56) | PNMTOPRK1SLC6A2HRH1SLC6A3 | |
| SCHEMBL7570310 | 0.84 | PNMT (0.47) | PNMTOPRK1SLC6A2HRH1SLC6A3 | |
| SCHEMBL178510 | 0.81 | PNMT (0.65) | PNMTSLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL7692070 | 0.80 | PNMT (0.50) | PNMTOPRK1SLC6A2HRH1SLC6A3 | |
| SCHEMBL7696707 | 0.80 | PNMT (0.50) | PNMTOPRK1SLC6A2HRH1SLC6A3 | |
| SCHEMBL7693446 | 0.80 | PNMT (0.50) | PNMTOPRK1SLC6A2HRH1SLC6A3 | |
| Hydrochloric Acid SCHEMBL23524229 | 0.79 | PNMT (0.62) | PNMTSLC6A2SLC6A3SLC6A4TAAR1 | |
| SCHEMBL10395509 | 0.79 | PNMT (0.68) | PNMTTAAR1SLC2A1CHRM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464345-A2 | TREATMENT OF VIRAL INFECTIONS | Biocopea Limited (GB) | 2012-06-20 | — | — | EP | claimed |
| WO-2011018653-A2 | TREATMENT OF VIRAL INFECTIONS | BIOCOPEA LIMITED (GB) | 2011-02-17 | — | — | WO | claimed |
| WO-2015095713-A1 | METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION | DEUTERX, LLC (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2464345-A2 | TREATMENT OF VIRAL INFECTIONS | Biocopea Limited (GB) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011018653-A2 | TREATMENT OF VIRAL INFECTIONS | BIOCOPEA LIMITED (GB) | 2011-02-17 | — | — | WO | disclosed |
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | FANG KEVIN QUN | 2010-05-20 | — | — | US | disclosed |
| US-6387956-B1 | ADMINISTERING TRAMADOL | UNIVERSITY OF CINCINNATI | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125070-A1 | Bupropion Metabolites and Methods of Their Synthesis and Use | MAOB, MAOA, HTR5A | PNMT 51/4885OPRK1 154/4885SLC6A2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.